Safety Checklist

This checklist is for prospective patients, families, and clinicians comparing stated safety practices at Ambio Ibogaine Clinic. It is not a medical clearance tool, a recommendation to pursue treatment, or a substitute for individualized clinical judgment. Start with the broader ibogaine safety questions Carden Flux tracks, then ask for answers that are specific, current, and documented.

Ibogaine has been associated with QT interval prolongation and serious cardiac events. The published review of ibogaine-related deaths and cardiac risk is a reason to prioritize careful screening rather than relying on marketing language. QTc is an ECG-derived correction of the QT interval; its clinical relevance is summarized in the Long QT syndrome reference overview.

A useful review also separates what a program says from what it can verify. The clinic-claim verification guide can help turn broad assurances about monitoring, emergency readiness, and aftercare into questions that have records, protocols, or named roles behind them.

Ask who is physically present during treatment, how many patients each clinician or observer covers, and whether that coverage changes overnight. Staffing ratios, professional roles, escalation authority, and transfer arrangements should be described plainly. Avoid inferring credentials or capabilities that a program has not published.

Continuous ECG monitoring, vital-sign observation, access to a functioning defibrillator, and emergency medications are not interchangeable claims. Ask whether monitoring is continuous, who reads alarms, how long observation continues, and what protocol addresses QTc management, abnormal rhythm, electrolyte concerns, or a change in clinical condition. For context, the American Heart Association overview of arrhythmia explains why rhythm disturbances require prompt recognition and response.

A safety claim is more useful when it identifies the decision-maker, the equipment, the trigger for action, and the route to higher-level care.

Regulatory status should be verified separately from a safety claim. Ask what authorization, local rules, and emergency-transfer arrangements apply where treatment is offered, including any program statements concerning Mexico or Malta. A treatment being available in a jurisdiction does not, by itself, establish a uniform clinical standard.

Ask whether the plan includes cardiology review when indicated, repeat ECG timing, clear instructions for new symptoms, and a handoff to clinicians at home. If medications have been changed, ask who owns the taper or re-start decision and how prescriptions, withdrawal risk, and relapse risk are addressed after leaving the program.

Psychological aftercare matters because a demanding treatment experience does not replace continuing support. Clarify what is included, who provides it, when it begins, how urgent concerns are handled, and what it cannot provide. Families considering cognitive or neurological claims can compare related questions through ibogaine cognition considerations, brain-aging safety context, and claims about brain de-aging.

Keep specialized conditions separate from generalized safety promises. For example, questions connected to concussion-related ibogaine claims, ALS-focused treatment questions, Alzheimer’s-related claims, and dementia discussions should not be used to assume efficacy or suitability. Each deserves condition-specific medical input and a careful account of uncertainty.